Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter lacking in Parkinsonian conditions. Benserazide, included in the formulation, blocks peripheral conversion of levodopa, ensuring more reaches the brain and reducing peripheral side effects.

The specific dose of Madopar is individualized by the prescribing clinician based on disease severity, patient age, and response. Dosage regimens can vary widely, and adjustments are made to achieve optimal symptom control while minimizing adverse effects.

Safety data for Madopar in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Madopar product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Madopar combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it generally provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Madopar tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Madopar is taken orally, usually with a glass of water. It may be taken with or without food, but patients are advised to avoid high‑protein meals close to dosing times, as protein can interfere with levodopa absorption.

Serious risks include the development of dyskinesia, severe orthostatic hypotension, psychiatric disturbances such as hallucinations or confusion, and rare but life‑threatening conditions like neuroleptic malignant‑like syndrome. Patients should report sudden mood changes, uncontrolled movements, or fainting episodes to their healthcare provider promptly.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, as well as those taking non‑selective MAO inhibitors. Caution is advised for individuals with narrow‑angle glaucoma, severe cardiovascular disease, or significant hepatic or renal impairment, and it should be avoided in such cases unless specifically directed by a physician.